Summary & Overview
CPT 78130: Red Blood Cell Survival Study, Autologous Radiolabel
CPT code 78130 denotes a diagnostic nuclear medicine study that measures red blood cell lifespan by reinjecting a patient’s own red blood cells labeled with a radiopharmaceutical. This test is used to evaluate hemolytic processes, unexplained anemia, or other conditions affecting erythrocyte survival. Nationally, the procedure is a specialized imaging service performed in hospital outpatient and dedicated nuclear medicine facilities and has implications for diagnostic workups where hemolysis or chronic blood loss is suspected.
Key payers included in the coverage landscape are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and the common modifiers associated with billing this code. The publication also summarizes expected use cases and operational considerations clinicians and billing staff encounter when arranging the study.
The report covers procedural benchmarks, payer coverage patterns, and coding guidance relevant to clinical staff and revenue cycle teams. It highlights factors that commonly affect utilization and reimbursement for diagnostic red blood cell survival testing and provides a national-level reference for institutions that perform nuclear medicine hematology studies.
Billing Code Overview
CPT code 78130 describes a diagnostic nuclear medicine procedure in which the provider studies the lifespan of a patient's red blood cells after reinjecting the patient's own red blood cells that have been labeled with a radiopharmaceutical. This service involves tagging autologous erythrocytes with a radiotracer, administering them back to the patient, and performing serial imaging or measurements to determine red blood cell survival.
-
Service type: Diagnostic nuclear medicine procedure assessing red blood cell survival
-
Typical site of service: Hospital outpatient imaging departments or nuclear medicine facilities
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with chronic anemia of unclear etiology is referred for a red blood cell (RBC) survival study to quantify RBC lifespan and evaluate hemolysis. The procedure begins in a nuclear medicine department. The patient has venous access for blood draw; autologous RBCs are drawn, labeled ex vivo with a technetium-99m or similar radiopharmaceutical, and reinjected. Serial blood samples and/or imaging are obtained over several hours to days to track labeled RBC disappearance. Results are interpreted by a nuclear medicine physician or hematologist and reported to the referring clinician to guide diagnosis of hemolytic anemia, evaluate transfusion efficacy, or assess suspected shortened RBC survival due to alloimmune hemolysis or mechanical destruction from prosthetic valves.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when reporting only the physician interpretation of the nuclear medicine study separate from the technical component. |
TC | Technical component | Use when reporting only facility/technical resources without physician interpretation. |